Spots Global Cancer Trial Database for HR+/HER2- Advanced Breast Cancer and Endocrine Resistance
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: HR+/HER2- Advanced Breast Cancer and Endocrine Resistance
Official Title: A Phase 2, International, Multicenter, Open-labeled, Randomized Trial of PAlbociclib and Fulvestrant vs. Standard Oral Capecitabine In Patients With Hormone Receptor (HR)+ / HER2- Advanced Breast Cancer and Documented Endocrine Resistance
Study ID: NCT03322215
Conditions
Study Description
Brief Summary: This is a randomized, 2-arm, open-label, multicenter, international phase II trial. A total of 196 patients will be included. The study will include patients with metastatic Hormone Receptor positive / Human Epidermal Growth Factor Receptor (HER2) negative breast cancer with progressive disease after endocrine treatment. Patients will be randomized (1:1) between two treatment arms: A. palbociclib + fulvestrant and b. capecitabine.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Sahlgrenska University Hospital, Göteborg, , Sweden
Skåne University Hospital, Malmö, , Sweden
S:t Görans Hospital, Stockholm, , Sweden
Karolinska University Hospital, Stockholm, , Sweden
Uppsala University Hospital, Uppsala, , Sweden
NHS Grampian, Aberdeen, , United Kingdom
Western General Hospital, Edinburgh, , United Kingdom
Beatson, Glasgow, , United Kingdom
NHS Ayshire and Arran, Kilmarnock, , United Kingdom
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
